Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222544 | 0.82 | MEN1 (0.56) | PTPN11GPR119MAPK8HDAC1CKS1B | |
| SCHEMBL23560892 | 0.81 | GPR119 (0.56) | PTPN11GPR119ACHECKS1BSKP1 | |
| SCHEMBL5222720 | 0.81 | HDAC1 (0.48) | PTPN11HDAC1 | |
| SCHEMBL16652717 | 0.79 | GPR119 (0.59) | PTPN11GPR119ACHECKS1BSKP1 | |
| SCHEMBL16651654 | 0.79 | PTPN11 (0.57) | PTPN11GPR119ACHECKS1BSKP1 | |
| SCHEMBL3607189 | 0.77 | GPR119 (0.57) | PTPN11GPR119ACHECKS1BSKP1 | |
| SCHEMBL5226822 | 0.77 | MAPK8 (0.46) | PTPN11GPR119MAPK8HDAC1CKS1B | |
| SCHEMBL20333119 | 0.77 | SUCNR1 (0.49) | MAPK8HDAC1MAPTMEN1KMT2A | |
| SCHEMBL16651862 | 0.77 | PTPN11 (0.55) | PTPN11GPR119ACHECKS1BSKP1 | |
| SCHEMBL24269707 | 0.77 | PTPN11 (0.55) | PTPN11GPR119ACHECKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501508-B1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| US-20050222410-A1 | Inhibitors of histone deacetylase | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1501508-A1 | INHIBITORS OF HISTONE DEACETYLASE | Astrazeneca AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003092686-A1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222410-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | PTPN11 4127/4885GPR119 1395/4885MAPK8 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.